Vision Measured by the Vimetrics CVA Compared With Chart Testing Under Similar Luminance and Contrast Conditions
NCT ID: NCT02028351
Last Updated: 2014-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2008-01-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is the following:
A)To gather age-related normative visual acuity data for the Vimetrics Central Vision Analyzer (CVA, Vimetrics, LLC, Media, Pa) B)To gather visual acuity data for patients with known ocular problems, including cataract and maculopathy.
C)To correlate and compare the CVA visual acuity findings with the acuity measured with standard LogMAR acuity charts viewed under similar conditions of contrast and lighting
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study
NCT05026658
Comparison of Four Different Aberrometers for Evaluation of Higher Order Visual Aberrations
NCT01230164
Evaluation of a Digital Visual Acuity Device vs. Standard Visual Acuity Measurements
NCT06431295
User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems
NCT07338513
Assessment of Ability Related to Vision
NCT01027312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
While these advances have improved the resolution and reliability of acuity measures, they require relatively cumbersome wall charts and do not provide any of the advantages of an interactive program that would enable a threshold to be approached by stimulus presentation on both the seeing as well as non-seeing sides.
The Vimetrics CVA is an interactive computer device that measures threshold visual acuity by presenting a Landolt-C with the gap randomly tumbled in one of 4 positions to which the patient responds with a response pad. The threshold is approached in a logarithmic, staircase fashion to define the test subject's acuity threshold with a resolution similar to letter by letter scoring in chart testing but with the ability to rapidly test under a number of conditions of luminance and contrast that simulate activities of daily living.
The CVA determination of visual acuity under six conditions of contrast and lighting will be compared with that acquired by logMAR chart testing under similar conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal
No Intervention
No interventions assigned to this group
Cataract
No intervention
No interventions assigned to this group
Maculopathy
No Intervention
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A visual acuity measured of 20/30 or better for which on examination the refractive error alone is determined to define the vision.
For individuals 65 years or greater, lens nuclear opalescence and brunescence that is less than or equal to NO3, NC3 according to the LOCS III grading system.
For individuals less than 65 years, lens nuclear opalescence and brunescence that is less than or equal to NO2, NC2, according to the LOCS III grading system.
Persons without systemic disease that would interfere with vision will be enrolled. Such diseases that would exclude a subject from this category would include diabetes, and other systemic diseases such as neurological disorders that the examiner determines may interfere with the vision of an eye.
For inclusion an eye would have had an ocular examination within three months as per the stated protocol.
A visual acuity worse than 20/30. The determination on examination by the examiner that the lens opacity alone defines the vision. For individuals less than age 65 the nuclear cataract will be denser than NO2, NC2 or contain other components (posterior cortical or posterior sub capsular) that will be documented. For individuals 65 years of age or older, the nuclear cataract will be greater than NO3, NC3 or contain other components that define the vision.
It is recognized that many individuals within this group will have diabetes or hypertension that may be the cause of the maculopathy or aggravate the maculopathy. However, such systemic diseases will not necessarily exclude such persons, unless the examiner determines that such diseases cause reduced vision in the eye that is not defined by the maculopathy.
For inclusion an eye would have had an ocular examination within three months with components according to the protocol as stated.
A visual acuity with chart testing worse than 20/30 for which on examination the maculopathy alone is determined to define the vision.
Exclusion Criteria
Normals:
Media opacity or retinal or optic nerve pathology that the examiner determines would affect the measured vision.
For individuals aged 65 or greater, eyes with nuclear opalescence and brunescence, according to the LOCS III grading system greater than NO3, NC3 or with other opacities will be excluded.
Eyes with Cataracts:
Eyes in which retinal or optic nerve pathology that the examiner determines would affect the measured vision.
Eyes with a best refracted chart acuity of 20/100 or worse because in such eyes the examiner will be prevented by the media opacity from adequately examining the fundus to determine if there is co-existent macular pathology.
Eyes with Maculopathy:
Eyes with a chart acuity of 20/400 or worse. Eyes having lens or optic nerve pathology that the examiner determines would affect the measured vision.
Eyes with dense cataract in which an adequate examination of the macula is prevented.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinclair Technologies, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen H. Sinclair, MD
Chief Medical Officer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen H Sinclair, MD
Role: PRINCIPAL_INVESTIGATOR
Sinclair Technologies, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pennsylvania College of Optometry
Elkins Park, Pennsylvania, United States
Gutstein Optik
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arditi A, Cagenello R. On the statistical reliability of letter-chart visual acuity measurements. Invest Ophthalmol Vis Sci. 1993 Jan;34(1):120-9.
Bourne RR, Rosser DA, Sukudom P, Dineen B, Laidlaw DA, Johnson GJ, Murdoch IE. Evaluating a new logMAR chart designed to improve visual acuity assessment in population-based surveys. Eye (Lond). 2003 Aug;17(6):754-8. doi: 10.1038/sj.eye.6700500.
Hazel CA, Elliott DB. The dependency of logMAR visual acuity measurements on chart design and scoring rule. Optom Vis Sci. 2002 Dec;79(12):788-92. doi: 10.1097/00006324-200212000-00011.
Raasch TW, Bailey IL, Bullimore MA. Repeatability of visual acuity measurement. Optom Vis Sci. 1998 May;75(5):342-8. doi: 10.1097/00006324-199805000-00024.
Bailey IL. New procedures for detecting early vision losses in the elderly. Optom Vis Sci. 1993 Apr;70(4):299-305. doi: 10.1097/00006324-199304000-00008.
Carkeet A. Modeling logMAR visual acuity scores: effects of termination rules and alternative forced-choice options. Optom Vis Sci. 2001 Jul;78(7):529-38. doi: 10.1097/00006324-200107000-00017.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VVS 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.